Bobby Lanier is a Rheumatology/Immunology physician affiliated with University of North Texas. OpenAlex indexes 44 publications with 4,794 citations (h-index 19).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6310 Southwest Blvd
Suite 200
Benbrook, TX 761093998
Telephone
817-731-9198Provider last certified this registry record 12 Jan 2023.
Industry payments
18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Healthcare Solutions, Inc.Program year20241 payment
- GENZYME CORPORATIONProgram year20241 payment
- Alcon Research LLCProgram year20233 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
100%Interleukin-5 Antagonist51.9%Nucala100%Part D<11 patientsCorticosteroid48.1%Symbicort100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The American College of Allergy, Asthma & Immunology: An 80-year legacy of accomplishments (1942-2022), part 3: Events and achievements (2012-2022)
Annals of Allergy Asthma & Immunology
2022 - Obesity influences the outcomes of anti‐IgE (omalizumab) therapy of asthma
Clinical & Experimental Allergy
2020 - Whole blood transcriptional variations between responders and non‐responders in asthma patients receiving omalizumab
Clinical & Experimental Allergy
2020 - Possible Protective Effect of Omalizumab on Lung Function Decline in Patients Experiencing Asthma Exacerbations
The Journal of Allergy and Clinical Immunology In Practice
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Bhella, MD
University of North Texas
Diana Castro, MD
University of North Texas
Rob Dickerman, DO, PhD
University of North Texas
Warren Marks, MD
University of North Texas
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”